| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01408849 Details | 2016-07-26 Interventional | 2 | 4 | Omeprazole Dyspepsia | Lack of adherence and huge loss of follow up. - | |||
| NCT01078974 Details | 2016-07-25 Interventional | 1 | 7 | Dexamethasone Pomalidomide Rituximab Waldenstrom Mac… Waldenstrom's M… | Safety concerns (IgM Flare) Pomalidomide and rituximab could have a synergistic effect on serum IgM levels and produce an IgM flare. The highest dose of pomalidomide in this trial was 1mg. The study was permanently closed to accrual given the safety concerns with the IgM flare. | |||
| NCT00417248 Details | 2016-07-25 Interventional | 1/2 | 8 | Etoposide Sorafenib Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | Negative sorafenib results from ESCAPE trial and safety concerns of regimen - | |||
| NCT00102947 Details | 2016-07-25 Interventional | 4 | - | Daptomycin Communicable Di… Infections Skin Diseases, … Soft Tissue Inf… | - - | |||
| NCT02731846 Details | 2016-07-22 Interventional | 3 | 0 | Albuterol Fluticasone Xhance Lung Diseases Lung Diseases, … Pulmonary Disea… | It has been determined on June 10th that the 205165 study will not progress. This decision has
been made prior to study start, no patients were screened. - | |||
| NCT00724841 Details | 2016-07-22 Interventional | 1/2 | 1 | Obatoclax Temozolomide Melanoma Metastatic Mela… | Study terminated prematurely due to financial contraints. - | |||
| NCT02675413 Details | 2016-07-20 Interventional | 4 | 0 | Dimethyl Fumara… Multiple Sclero… Multiple Sclero… Sclerosis | Principal Investigator decided to withdraw. - | |||
| NCT01701063 Details | 2016-07-20 Interventional | 1/2 | 42 | Peginterferon a… Ribavirin Hepatitis Hepatitis A Hepatitis C | - Study was terminated early because it was determined that telaprevir/Peg-IFN/RBV regimen did not present a meaningful therapeutic treatment over existing interferon-free regimens and was unlikely to be used for participants aged 3 to 17 years. | |||
| NCT01390441 Details | 2016-07-20 Interventional | 1 | 100 | Acetaminophen Loratadine Methotrexate Methylprednisol… Rituximab Arthritis Arthritis, Rheu… Rheumatoid Arth… | The study was terminated early by the Sponsor for business reasons. - | |||
| NCT00627835 Details | 2016-07-20 Interventional | 1 | 0 | Cisplatin Sorafenib Carcinoma Carcinoma, Squa… Squamous Cell C… Locally Advance… | Site decided not to open this study - | |||
| NCT02221232 Details | 2016-07-18 Interventional | 2 | 64 | Chlorhexidine Chlorhexidine g… Ethanol Surgical Wound … Surgical Site I… | To assess product performance (test and reference products), move into further testing. - | |||
| NCT01723501 Details | 2016-07-18 Interventional | 2/3 | 0 | Chlorhexidine Neonatal Sepsis Sepsis Neonatal Mortal… | The study was not started and prematurely closed. - | |||
| NCT00297232 Details | 2016-07-15 Interventional | 3 | [3 Refs] | 1094 | Natalizumab Multiple Sclero… Multiple Sclero… Sclerosis Relapsing-Remit… | - Sponsor decided to terminate the study prior to all subjects reaching Week 480 as the primary objective was deemed to have been met and only approximately 45% of the original STRATA population remained in the study at the time of study termination. | ||
| NCT01577524 Details | 2016-07-14 Interventional | 2 | 58 | Povidone Povidone-Iodine Surgical Wound … Surgical Site I… | We had very low recruitment rates that would have resulted in several years being added to the
study to achieve an appropriate sample size. - | |||
| NCT02599701 Details | 2016-07-13 Interventional | 4 | 8 | Gabapentin Sleep | Gabapentin increased hypopnea-apnea index in the first 8 recruited subjects. - | |||
| NCT01226745 2010-018705-11 Details | 2016-07-12 Interventional | 2 | [1 Refs] | 340 | Ceralifimod Multiple Sclero… Multiple Sclero… Sclerosis | Merck has decided to not pursue phase 3 development of ceralifimod (ONO-4641). The decision was
not related to any safety and efficacy findings Company has decided to not pursue phase 3 development of ceralifimod (ONO-4641). The decision was not related to any safety and efficacy findings. | ||
| NCT00053339 Details | 2016-07-12 Interventional | 3 | 0 | Tamoxifen Trastuzumab Breast Neoplasm… Recurrent Breas… Stage IV Breast… | The study was not activated. - | |||
| NCT02703233 Details | 2016-07-11 Interventional | 4 | 0 | Nitrous Oxide Lacerations Abscess | Feasibility - | |||
| NCT02347033 Details | 2016-07-11 Interventional | 4 | 5 | Sertraline Anxiety Disorde… Generalised Anx… | Difficulties with recruitment during the internal pilot phase - | |||
| NCT02152059 Details | 2016-07-06 Interventional | 2 | 0 | Nintedanib Hypersensitivit… Lung Neoplasms Small Cell Lung… Platinum-sensit… Small Cell Lung… | contract issues - |